Collegium Pharmaceutical, Inc. Proceeds from (Repayments of) Restricted Cash, Financing Activities
Collegium Pharmaceutical, Inc. (COLL) reported Proceeds from (Repayments of) Restricted Cash, Financing Activities of -$16.00 thousand for the 12-month period ending 2015-12-31, per its 10-K filed 2018-03-07.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromRepaymentsOfRestrictedCashFinancingActivities · last filed 2018-03-07
- Collegium Pharmaceutical, Inc. proceeds from (repayments of) restricted cash, financing activities for fiscal 2015 was -$16.00K.
| Period end | Proceeds from (Repayments of) Restricted Cash, Financing Activities 12 month |
|---|---|
| 2015-12-31 | -$16.00K 10-K · filed 2018-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |